ST Pharm

Beta

KRX Filings & Disclosures 2026

Management Discussion & Analysis

• • Revenue KRW 331.7B (+21.2% YoY), Operating profit KRW 54.9B (+98.4%), Net income KRW 54.6B (+68.1%) in FY2025
• • Oligo API CDMO segment drove growth with revenue up 35% to KRW 237.6B; management cites "commercialization project increase to 5 cases"

Risk Factors

• • USD foreign currency exposure KRW 133.38B assets, KRW 13.14B liabilities, 10% USD move ±KRW 9.16B after-tax profit impact FY2025
• • Short-term financial liabilities within 1 year KRW 64.84B (buying payables KRW 11.80B, lease liabilities KRW 1.28B, borrowings KRW 31.65B, other liabilities KRW 20.39B) FY2025

Business Overview

• • Oligonucleotide CDMO global rank 3rd with new 2nd oligo plant started Q4 2025, contributing to sales from 2026
• • Entered mRNA business Nov 2020; secured 177B KRW LNP lipid supply contract May 2022 and SmartCap® supply contract Aug 2024

What are the latest ST Pharm DART filings in 2026?

ST Pharm (KRX code 237690) has filed an annual report on March 18, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did ST Pharm file its most recent annual report?

ST Pharm filed its most recent annual report on March 18, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is ST Pharm's KRX stock code?

ST Pharm's KRX stock code is 237690. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 237690 to look up all ST Pharm disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does ST Pharm file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for ST Pharm.

Where can I find ST Pharm financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from ST Pharm annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.